Regulus Therapeutics (RGLS) Competitors $8.16 0.00 (0.00%) As of 06/25/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RGLS vs. LGND, BCRX, FOLD, CLDX, INVA, DVAX, MNKD, OPK, NVAX, and GERNShould you be buying Regulus Therapeutics stock or one of its competitors? The main competitors of Regulus Therapeutics include Ligand Pharmaceuticals (LGND), BioCryst Pharmaceuticals (BCRX), Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), Innoviva (INVA), Dynavax Technologies (DVAX), MannKind (MNKD), OPKO Health (OPK), Novavax (NVAX), and Geron (GERN). These companies are all part of the "biotechnology" industry. Regulus Therapeutics vs. Its Competitors Ligand Pharmaceuticals BioCryst Pharmaceuticals Amicus Therapeutics Celldex Therapeutics Innoviva Dynavax Technologies MannKind OPKO Health Novavax Geron Ligand Pharmaceuticals (NASDAQ:LGND) and Regulus Therapeutics (NASDAQ:RGLS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings. Which has more risk & volatility, LGND or RGLS? Ligand Pharmaceuticals has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Comparatively, Regulus Therapeutics has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500. Which has higher earnings and valuation, LGND or RGLS? Ligand Pharmaceuticals has higher revenue and earnings than Regulus Therapeutics. Ligand Pharmaceuticals is trading at a lower price-to-earnings ratio than Regulus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLigand Pharmaceuticals$167.13M13.20-$4.03M-$7.12-16.07Regulus TherapeuticsN/AN/A-$46.36M-$0.73-11.18 Do analysts prefer LGND or RGLS? Ligand Pharmaceuticals currently has a consensus target price of $146.14, indicating a potential upside of 27.76%. Regulus Therapeutics has a consensus target price of $8.50, indicating a potential upside of 4.17%. Given Ligand Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Ligand Pharmaceuticals is more favorable than Regulus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ligand Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Regulus Therapeutics 0 Sell rating(s) 5 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.29 Is LGND or RGLS more profitable? Regulus Therapeutics has a net margin of 0.00% compared to Ligand Pharmaceuticals' net margin of -73.07%. Ligand Pharmaceuticals' return on equity of -7.83% beat Regulus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Ligand Pharmaceuticals-73.07% -7.83% -6.92% Regulus Therapeutics N/A -57.53%-53.26% Does the media favor LGND or RGLS? In the previous week, Ligand Pharmaceuticals had 7 more articles in the media than Regulus Therapeutics. MarketBeat recorded 7 mentions for Ligand Pharmaceuticals and 0 mentions for Regulus Therapeutics. Ligand Pharmaceuticals' average media sentiment score of 0.92 beat Regulus Therapeutics' score of 0.00 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Ligand Pharmaceuticals Positive Regulus Therapeutics Neutral Do insiders & institutionals believe in LGND or RGLS? 91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.4% of Regulus Therapeutics shares are owned by institutional investors. 7.0% of Ligand Pharmaceuticals shares are owned by insiders. Comparatively, 4.4% of Regulus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryLigand Pharmaceuticals beats Regulus Therapeutics on 11 of the 15 factors compared between the two stocks. Get Regulus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RGLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RGLS vs. The Competition Export to ExcelMetricRegulus TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$564.92M$2.43B$5.53B$9.02BDividend YieldN/A1.78%5.22%3.99%P/E Ratio-11.189.1527.7920.25Price / SalesN/A680.43426.06119.26Price / CashN/A21.7726.2128.59Price / Book6.974.558.045.65Net Income-$46.36M$31.26M$3.18B$249.15M7 Day PerformanceN/A2.98%2.89%2.91%1 Month Performance-0.73%3.46%1.67%4.11%1 Year Performance391.57%0.77%34.53%20.98% Regulus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RGLSRegulus Therapeutics1.5861 of 5 stars$8.16flat$8.50+4.2%N/A$564.92MN/A-11.1830Gap UpLGNDLigand Pharmaceuticals4.8114 of 5 stars$113.68-0.4%$146.14+28.6%+35.6%$2.20B$167.13M-15.9780BCRXBioCryst Pharmaceuticals4.4714 of 5 stars$8.96-4.3%$16.89+88.5%+37.2%$1.96B$450.71M-34.46530FOLDAmicus Therapeutics3.694 of 5 stars$5.73-3.4%$16.22+183.1%-38.6%$1.83B$528.29M-63.66480CLDXCelldex Therapeutics3.0709 of 5 stars$20.35+0.3%$50.11+146.2%-38.1%$1.35B$7.02M-7.54150INVAInnoviva3.8999 of 5 stars$20.09+0.7%$55.00+173.8%+17.4%$1.25B$358.71M-19.89100DVAXDynavax Technologies4.3926 of 5 stars$9.92+0.1%$24.00+141.9%-8.6%$1.19B$277.25M-19.08350Positive NewsMNKDMannKind2.5282 of 5 stars$3.74-0.5%$10.33+176.3%-29.7%$1.14B$285.50M37.40400OPKOPKO Health4.449 of 5 stars$1.32flat$2.75+108.3%+6.7%$1.05B$713.10M-18.852,997NVAXNovavax4.497 of 5 stars$6.30-1.1%$17.00+169.8%-42.9%$1.03B$682.16M2.381,990GERNGeron2.8523 of 5 stars$1.41-5.4%$5.06+259.0%-68.5%$949.01M$76.99M-6.7170 Related Companies and Tools Related Companies Ligand Pharmaceuticals Alternatives BioCryst Pharmaceuticals Alternatives Amicus Therapeutics Alternatives Celldex Therapeutics Alternatives Innoviva Alternatives Dynavax Technologies Alternatives MannKind Alternatives OPKO Health Alternatives Novavax Alternatives Geron Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RGLS) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regulus Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regulus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RGLS Stock Alerts